Upmc Hillman Cancer Center(Univ of Pittsburgh)

Pittsburgh, Pennsylvania 15232-1309

3 studies enrolling now · 6 studies all time

What they study most

Acute Myeloid Leukemia, Advanced Solid Tumor, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Chronic Lymphocytic Leukemia, Extragonadal Yolk Sac Tumors, Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Local Advanced Hepatocellular Carcinoma, Mature B-Cell Malignancies, Metastatic Hepatocellular Carcinoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm

Studies at this site

• A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) — Recruiting now
• A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors — Recruiting now
• A Study of BGB-11417 in Participants With Myeloid Malignancies — Recruiting now
• Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies — Running, not enrolling
• A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors — Stopped early
• Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors — Completed